U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. FDA Organization
  4. Oncology Center of Excellence
  5. Creating a Public-Private Partnership to Support Development of Anti-Cancer Therapies for Ultra-Rare Tumor Indications
  1. Oncology Center of Excellence

Creating a Public-Private Partnership to Support Development of Anti-Cancer Therapies for Ultra-Rare Tumor Indications

FNIH, NCI, and FDA Public Meeting Notice

On August 24, 2023, the Foundation for the National Institutes of Health (FNIH), the National Cancer Institute (NCI), and the Oncology Center of Excellence at the Food and Drug Administration (FDA) will conduct a virtual meeting to discuss plans for creating a public-private partnership (PPP) to guide and support the development of new treatments for patients with ultra-rare cancers. Many pediatric and adult ultra-rare cancers have actionable oncogenic drivers not present in more common cancers; however, there is limited economic incentive to encourage concerted and coordinated efforts to develop drugs for these ultra-rare cancers.
 
During this multi-stakeholder meeting, participants will discuss options for a collaborative open-science, open-drug development process for targeted therapies for ultra-rare cancer indications. FNIH will solicit feedback and suggestions pre- and post-meeting from the ultra-rare cancer community on the proposed PPP plans and gauge interest and resources available for drug development in this arena. All stakeholders with an interest in providing feedback on this effort are encouraged to register using the Zoom link information below.

Meeting Date: August 24, 2023
Meeting Time: 11:00-15:00 US Eastern Time
Meeting Format: Virtual

Register for this webinar at: 
https://fnih.zoom.us/webinar/register/WN_UmmtJYp1TzehUYaqx0RFyQ
 
After registering, you will receive a confirmation email containing information about joining the webinar.  

Workshop Materials

If you have any questions prior to the meeting, please feel free to contact the FNIH team: Stacey Adam (sadam@fnih.org), Dana Connors (dconnors@fnih.org), and Katherine Lambertson (klambertson@foundationfornih.org).

Back to Top